Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening.
Oikonomou A, Watrin T, Valsecchi L, Scharov K, Savino AM, Schliehe-Diecks J, Bardini M, Fazio G, Bresolin S, Biondi A, Borkhardt A, Bhatia S, Cazzaniga G, Palmi C. Oikonomou A, et al. Among authors: borkhardt a. Heliyon. 2024 Jul 3;10(13):e34033. doi: 10.1016/j.heliyon.2024.e34033. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39071567 Free PMC article.
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L, Yang J, Schliehe-Diecks J, Dienstbier N, Vogt M, Gebing P, Bachmann LM, Sönnichsen M, Lenz T, Stühler K, Schöler A, Borkhardt A, Bhatia S, Hansen FK. Sinatra L, et al. Among authors: borkhardt a. J Med Chem. 2022 Dec 22;65(24):16860-16878. doi: 10.1021/acs.jmedchem.2c01659. Epub 2022 Dec 6. J Med Chem. 2022. PMID: 36473103
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia.
Palmi C, Bresolin S, Junk S, Fazio G, Silvestri D, Zaliova M, Oikonomou A, Scharov K, Stanulla M, Moericke A, Zimmermann M, Schrappe M, Buldini B, Bhatia S, Borkhardt A, Saitta C, Galbiati M, Bardini M, Lo Nigro L, Conter V, Valsecchi MG, Biondi A, Te Kronnie G, Cario G, Cazzaniga G. Palmi C, et al. Among authors: borkhardt a. Hemasphere. 2023 May 26;7(6):e892. doi: 10.1097/HS9.0000000000000892. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37304931 Free PMC article.
Development of the first geldanamycin-based HSP90 degraders.
Wurnig S, Vogt M, Hogenkamp J, Dienstbier N, Borkhardt A, Bhatia S, Hansen FK. Wurnig S, et al. Among authors: borkhardt a. Front Chem. 2023 Jun 28;11:1219883. doi: 10.3389/fchem.2023.1219883. eCollection 2023. Front Chem. 2023. PMID: 37448856 Free PMC article.
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A, Valsecchi L, Quadri M, Watrin T, Scharov K, Procopio S, Tu JW, Vogt M, Savino AM, Silvestri D, Valsecchi MG, Biondi A, Borkhardt A, Bhatia S, Cazzaniga G, Fazio G, Bardini M, Palmi C. Oikonomou A, et al. Among authors: borkhardt a. Biochem Pharmacol. 2023 Nov;217:115809. doi: 10.1016/j.bcp.2023.115809. Epub 2023 Sep 17. Biochem Pharmacol. 2023. PMID: 37717691 Free article.
Proteogenomic profiling uncovers differential therapeutic vulnerabilities between TCF3::PBX1 and TCF3::HLF translocated B-cell acute lymphoblastic leukemia.
Blumel L, Bernardi F, Picard D, Diaz JT, Jepsen VH, Hasselmann R, Schliehe-Diecks J, Bartl J, Qin N, Bornhauser B, Bhatia S, Marovka B, Marsaud V, Dingli F, Loew D, Stanulla M, Bourqin JP, Borkhardt A, Remke M, Ayrault O, Fischer U. Blumel L, et al. Among authors: borkhardt a. Haematologica. 2024 Jul 1;109(7):2290-2296. doi: 10.3324/haematol.2023.283928. Haematologica. 2024. PMID: 38426288 Free PMC article. No abstract available.
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia.
Saettini F, Guerra F, Mauri M, Salter CG, Adam MP, Adams D, Baple EL, Barredo E, Bhatia S, Borkhardt A, Brusco A, Bugarin C, Chinello C, Crosby AH, D'Souza P, Denti V, Fazio G, Giuliani S, Kuehn HS, Amel H, Elmi A, Lo B, Malighetti F, Mandrile G, Martín-Nalda A, Mefford HC, Moratto D, Emam Mousavi F, Nelson Z, Gutiérrez-Solana LG, Macnamara E, Michaud V, O'Leary M, Pagani L, Pavinato L, Santamaria PV, Planas-Serra L, Quadri M, Raspall-Chaure M, Rebellato S, Rosenzweig SD, Roubertie A, Holzinger D, Deal C, Vockley CW, Savino AM, L Stoddard J, Uhlig HH, Pujol A, Magni F, Paglia G, Cazzaniga G, Piazza R, Barberis M, Biondi A. Saettini F, et al. Among authors: borkhardt a. J Clin Immunol. 2024 Sep 23;45(1):15. doi: 10.1007/s10875-024-01793-8. J Clin Immunol. 2024. PMID: 39312004
Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.
Fischer F, Schliehe-Diecks J, Tu JW, Gangnus T, Ho YL, Hebeis M, Alves Avelar LA, Scharov K, Watrin T, Kemkes M, Stachura P, Daugs K, Biermann L, Kremeyer J, Horstick N, Span I, Pandyra AA, Borkhardt A, Gohlke H, Kassack MU, Burckhardt BB, Bhatia S, Kurz T. Fischer F, et al. Among authors: borkhardt a. J Med Chem. 2024 Dec 12;67(23):21223-21250. doi: 10.1021/acs.jmedchem.4c02024. Epub 2024 Nov 27. J Med Chem. 2024. PMID: 39602240
494 results